Endometriosis - Woman holding stomach in pain

The Problem of Endometriosis in the UK

July 7, 2025
Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology

When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?

Toast Burning

Five facts about UV exposure and sun safety

July 7, 2025
Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare

1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …

LEO Pharma appoints Helle Hedegaard Juhl as EVP of global people & corporate affairs

July 7, 2025
Manufacturing and Production Dermatology, Helle Hedegaard Juhl, LEO Pharma, Skin, dermatology

Danish dermatology company, LEO Pharma, announced the appointment of new executive vice president (EVP) of global people and corporate affairs, …

Jens Holstein, Alexandra Ogilvie and Ulrich Dauer

Mallia strengthens its advisory board as it accelerates hair loss treatment

July 7, 2025
Manufacturing and Production Dermatology, Skin, biopharma, dermatology, hair loss, mallia

German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its …

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025
Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …

The quiet crisis: why medicines operations matter more than ever in the ICB era

July 4, 2025
Business Services, Market Access Gateway to Local Adoption, Integrated Care Board, NHS, Primary Care Networks, Visions4Health

In the second of the Gateway to Local Access series, Vision4Health caught up with Dr Graham Duce, ICB GP Prescribing …

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

Nick Challoner appointed CEO of Ingenza to drive further growth

July 4, 2025
Business Services, Manufacturing and Production CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president

Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive …

Biocon Biologics gains EU approval for bone health therapies

July 4, 2025
Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …

Ferring strengthens evidence for flexible dosing of follitropin delta in IVF

July 3, 2025
Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine

Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …

PharmNovo submits CTA for non-addictive neuropathic pain therapeutic

July 1, 2025
Medical Communications, Research and Development Clinical Trial Application (CTA), Neurology, Pain, PharmNovo, chronic cough, clinical trials, migraine, neuropathic pain, opioid use disorder, opioid withdrawal syndrome

Swedish biotech PharmNovo has submitted a clinical trial application (CTA) to the Spanish health authorities for its lead candidate PN6047, …

hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025
Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025
Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …

Defining neighbourhood working: big picture or local lens?

June 27, 2025
Business Services Gateway to Local Adoption, NHS England, neighbourhood working

In the first of the Gateway to Local Adoption series, Visions4Health caught up with Dr Nick Merrifield to discuss his views on …

Inizio Evoke appoints Kelly Cusumano to drive strategic growth and innovation

June 27, 2025
Business Services, Marketing Consultancies, Medical Communications Corporate, Evoke Comms, Inizio Evoke, business strategist, executive vice president, marketing and communications

Inizio Evoke, a global health marketing and communications platform, has appointed Kelly Cusumano as executive vice president, growth and client …

Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases

June 27, 2025
Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners

Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …

The Gateway to Local Adoption Series

Latest content